STI Stock Trade Intelligence
IMU

IMUGENE LIMITED

Health Care · ASX:IMU
$0.0350
▼ -2.78%
Market cap
$19M
Turnover
$45,690
Last price
$0.0350
Day change
-2.78%
Announcements
17
Range, past year
Open 0.300 · Low 0.010 · Now 0.035 · High 0.460
Open IMU in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

IMU momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
27/100
Wyckoff phase
Accumulation26d
Trend stage
Neutral
1 Day
-2.8%
1 Week
-7.9%
1 Month
-2.8%
1 Year
-88.3%
RSI
45
Avg daily range
9.2%

IMUGENE LIMITED scores 27 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 26 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently matching and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -58.9%
  • High volatility (ATR 9.2%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
IMU appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

IMU announcements

Recent price-sensitive releases.
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-19 Further Responses in azer-cel Phase 1b Trial Progress Report
  • 2026-10-05 azer-cel BTKi Cohort Reports new Complete & Partial Response Progress Report
  • 2026-08-28 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-27 Third response in concurrent BTKi Cohort of azer-cel Trial Progress Report
  • 2026-07-27 CEO Resignation CEO/Managing Director - Appointment Resignation
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.